Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease

  • Marie-Odile Habert
  • Leonardo Cruz de Souza
  • Foudil Lamari
  • Nelle Daragon
  • Serge Desarnaud
  • Claude Jardel
  • Bruno Dubois
  • Marie Sarazin
Short Communication



Our aim was to study the correlations between cerebrospinal fluid (CSF) biomarker levels such as β-amyloid 42 (Aβ42), total and phosphorylated tau protein (T-tau and P-tau) and brain perfusion SPECT in Alzheimer’s disease (AD) using a voxel-based methodology.


Patients (n = 31) with clinical features of AD (n = 25) or amnestic mild cognitive impairment (aMCI) (n = 6) were retrospectively included. All subjects underwent the same clinical, neuropsychological and neuroimaging tests. They had a lumbar puncture and a brain perfusion (99mTc-ECD) SPECT within a time interval of 10 (±26) days. Correlations between CSF biomarker concentrations and perfusion were studied using SPM2 software. Individual normalised regional activity values were extracted from the eligible clusters for calculation of correlation coefficients.


No significant correlation was found between Aβ42 concentrations and brain perfusion. A significant correlation (p < 0.01, corrected) was found between T-tau or P-tau concentrations and perfusion in the left parietal cortex.


Our results suggest a strong correlation between T-tau and P-tau levels and decreased brain perfusion in regions typically affected by neuropathological changes in AD.


SPECT rCBF Alzheimer’s disease Mild cognitive impairment CSF biomarkers 

Supplementary material

259_2009_1285_Fig3_ESM.gif (25 kb)
Supplementary Figure 1

Anatomical localisations of peaks of hypoperfusion (p < 0.05, corrected for multiple comparisons) obtained from comparison between 31 patients (25 AD, 6 aMCI) and 24 age-matched healthy subjects with SPM2. Perfusion was decreased in the bilateral posterior associative cortex, including posterior cingulate regions, and in the left prefrontal dorsolateral cortex. (GIF 25 kb)

259_2009_1285_Fig3_ESM.tif (879 kb)
High resolution image file (TIFF 879 kb).


  1. 1.
    Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003;2(10):605–13.CrossRefPubMedGoogle Scholar
  2. 2.
    Ashford JW, Shih WJ, Coupal J, Shetty R, Schneider A, Cool C, et al. Single SPECT measures of cerebral cortical perfusion reflect time-index estimation of dementia severity in Alzheimer's disease. J Nucl Med 2000;41(1):57–64.PubMedGoogle Scholar
  3. 3.
    Bradley KM, O’Sullivan VT, Soper ND, Nagy Z, King EM, Smith AD, et al. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer’s disease. Brain 2002;125(Pt 8):1772–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Tsolaki M, Sakka V, Gerasimou G, Dimacopoulos N, Chatzizisi O, Fountoulakis KN, et al. Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer’s type, other types of dementia, and control subjects. Am J Alzheimers Dis Other Demen 2001;16(1):21–31.CrossRefPubMedGoogle Scholar
  5. 5.
    Ceravolo R, Borghetti D, Kiferle L, Tognoni G, Giorgetti A, Neglia D, et al. CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer’s disease. Brain Res Bull 2008;76(1–2):80–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Haense C, Buerger K, Kalbe E, Drzezga A, Teipel SJ, Markiewicz P, et al. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer’s disease. Eur J Neurol 2008;15(11):1155–62.CrossRefPubMedGoogle Scholar
  7. 7.
    Arlt S, Brassen S, Jahn H, Wilke F, Eichenlaub M, Apostolova I, et al. Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2009;36(7):1090–100.CrossRefPubMedGoogle Scholar
  8. 8.
    Vukovich R, Perneczky R, Drzezga A, Förstl H, Kurz A, Riemenschneider M. Brain metabolic correlates of cerebrospinal fluid beta-amyloid 42 and tau in Alzheimer’s disease. Dement Geriatr Cogn Disord 2009;27(5):474–80.CrossRefPubMedGoogle Scholar
  9. 9.
    Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6(8):734–46.CrossRefPubMedGoogle Scholar
  10. 10.
    Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66(3):382–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, et al. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol 2009;66(5):632–7.CrossRefPubMedGoogle Scholar
  12. 12.
    de Jong D, Jansen RW, Pijnenburg YA, van Geel WJ, Borm GF, Kremer HP, et al. CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry 2007;78(9):936–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 2006;129(Pt 11):2856–66.CrossRefPubMedGoogle Scholar
  14. 14.
    Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE, et al. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging 2008;29(10):1466–73.CrossRefPubMedGoogle Scholar
  15. 15.
    Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15(1):273–89.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Marie-Odile Habert
    • 1
    • 2
    • 5
  • Leonardo Cruz de Souza
    • 3
  • Foudil Lamari
    • 4
  • Nelle Daragon
    • 2
  • Serge Desarnaud
    • 2
  • Claude Jardel
    • 4
  • Bruno Dubois
    • 3
  • Marie Sarazin
    • 3
  1. 1.Université Pierre et Marie Curie-Paris 6, INSERMUMR-S 678ParisFrance
  2. 2.Department of Nuclear MedicineCHU Pitié-Salpêtrière, AP-HPParisFrance
  3. 3.Research and Resource Memory Centre and INSERM U610CHU Pitié-Salpêtrière, AP-HPParisFrance
  4. 4.Department of Metabolic BiochemistryCHU Pitié-Salpêtrière, AP-HPParisFrance
  5. 5.Department of Nuclear MedicineHôpital Pitié-SalpêtrièreParisFrance

Personalised recommendations